Latest news with #Crohns
Yahoo
01-06-2025
- General
- Yahoo
/R E P E A T -- MEDIA ADVISORY - Walking in Support of the 322,000+ people in Canada with Crohn's or colitis/
INTERVIEW & PHOTO OPPORTUNITIES Every 48 minutes – another Canadian is diagnosed with Crohn's or colitis; by 2035, 470,000+ Canadians will be living with IBD TORONTO, May 30, 2025 /CNW/ - WHAT: On Sunday, June 1, 2025, Crohn's and Colitis Canada, along with Canada's Inflammatory Bowel Disease (IBD) community, will participate in Gutsy Walk, a national fundraising event that supports the 322,000+ people living with Crohn's or colitis. Gutsy Walk, Crohn's and Colitis Canada's largest fundraising initiative, raises funds that go directly towards national research, advocacy, and patient programs. WHO: Those living with Crohn's or colitis, community members, friends, family and local representatives. WHEN: Sunday, June 1, 2025. Event start times may vary by location. WHERE: 30+ locations nationwide – from coast to coast. To register a team, donate and view locations, visit: WHY: There is no cure for Crohn's or colitis. Treatment focuses on achieving and maintaining remission, minimizing complications, preventing lasting intestinal damage, and improving quality of life. Crohn's and colitis are lonely diseases, with stigma and isolation added onto physical symptoms. SPOKESPERSON QUOTES: Jayda Sutton of Oakville, ON: Longstanding participant who lives with colitis and is the Ontario Provincial Honourary Chair. "I walk to honour my journey, my son Grayson who passed away at eight months gestation due to complications related to my colitis, my daughter Alyssa, my husband Chris, my parents and everyone who has stood with me. I want to use my story to highlight the quiet victories – getting back up when you feel defeated." Kate Lee, VP, Research & Patient Programs, Crohn's and Colitis Canada: "Gutsy Walk is a celebration of resilience. These are isolating diseases, which makes Gutsy Walk an important moment for those affected to come together and contribute to a better future for themselves." ABOUT CROHN'S AND COLITIS CANADA We are on a relentless journey to cure Crohn's and colitis and improve the quality of life of everyone affected by these diseases. Get the latest Gutsy Walk information on Instagram and Facebook - @gutsywalk and @getgutyscanada, as well as For information on Crohn's and Colitis Canada, visit To request visuals or coordinate interviews with Gutsy Walk participants or Crohn's and Colitis Canada, please contact: Alexandra SOURCE Crohn's & Colitis Canada View original content to download multimedia:
RNZ News
07-05-2025
- Health
- RNZ News
Canterbury IBD cases tripled over last two decades, likely to double nationally in next 20 years
Photo: University of Otago Known cases of inflammatory bowel disease have tripled in Canterbury in the past two decades - and will likely keep rising dramatically in New Zealand, a world-leading study has revealed. Otago University experts have worked with researchers around the globe on the study published in the prestigious medical journal Nature this week. Inflammatory bowel disease (IBD) is made up of Crohns and ulcerative colitis which cause ulcers and inflammation in the gut and have a range of nasty symptoms including abdominal pain, rectal bleeding, fever and sometimes inflammation of other organs. The study predicts cases will double in Aotearoa in the next 20 years. It set out to categorise IBD rates in different parts of the world, to help countries set up their health systems up to cope with growing numbers. One of the co-authors, Otago's Professor Richard Gearry, is a working gastroenterologist who treats patients with the diseases. He was surprised to realise the big increase in rates in Canterbury - from 1420 to 4000 cases - as the research team reviewed previous studies done since 2006. There were about 20,000 New Zealanders with IBD in New Zealand but that was expected to be more than 40,000 by 2025, the study found. Cases were particularly rising in Māori and Pacific peoples. IBD could be treated or managed with drugs or surgery and it was better to be diagnosed as early as possible. "To keep up with rising demand, our health system needs to plan ahead and invest more in care designed to specifically meet the needs of people with IBD. We also need to focus on more prevention, research and earlier intervention," Gearry said. "Many patients experience years of diagnostic delay, resulting in worse outcomes, which is why more resourcing and investment is sorely needed." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Business Standard
05-05-2025
- Business
- Business Standard
Biocon edges higher after biologics arm secures multiple market access deals for Yesintek
Biocon advanced 3.17% to Rs 328.75 after Biocon Biologics (BBL) secures multiple market access agreements in the United States for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab), covering over 100 million lives. These agreements include key placements on national and regional formularies. Express Scripts added Yesintek to its National Preferred Formulary (NPF) effective 21 March 2025. Cigna included Yesintek on its commercial formulary starting 21 March 2025. UnitedHealthcare has added Yesintek to various formularies: commercial from 01 May 2025; managed Medicaid from 01 March 2025; and Medicare from 01 June 2025. CVS Health will include Yesintek beginning 01 July 2025, and Optum Rx will add it to its premium and select formularies from 01 July 2025. Furthermore, Yesintek has been selected on formularies by Navitus, Costco Health Solutions, MedImpact, Priority Health, University of Pittsburgh Medical Center (UPMC), and numerous other regional health plans. Notably, Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems have designated Yesintek as their exclusive ustekinumab product. BBL is also in the final stages of securing formulary agreements with additional commercial carriers, the company stated. Yesintek, a monoclonal antibody that inhibits IL-12 and IL-23 signaling associated with immune-mediated diseases, received U.S. FDA approval in December 2024. It is approved for the treatment of Crohns disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: Yesintek (Ustekinumab kfce) represents an important milestone for Biocon Biologics, as this is the first product we have launched in the United States as a fully integrated biosimilars company. The strong adoption of Yesintek by payors in the U.S. reflects their confidence in our science, supply reliability, and commercial capability. Biocon Biologics, a subsidiary of Biocon, is a fully integrated, global biosimilars company. It has commercialized eight biosimilars in key emerging markets and advanced markets. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. Biocon is a biopharmaceutical company manufacturing APIs, and generic formulations. It is also involved in research and development. The companys consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25.
